Comparison of therapeutic effects of denosumab and romosozumab using Propensity Score Matching in postmenopausal osteoporosis patients
Not Applicable
Recruiting
- Conditions
- Primary osteoprosisosteoprosisD0 1 0 0 2 4
- Registration Number
- JPRN-jRCT1041200090
- Lead Sponsor
- Kobayakawa Tomonori
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 150
Inclusion Criteria
primary osteoporosis
Exclusion Criteria
1. Previous romosozumab or denosumab use.
2. hypocalcemia
3. Cardiovascular events within 1 year
4. Pregnant or lactating women, those who wish to become pregnant
5. Patients judg ed to be inappropriate for study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bone density chang e (lumbar spine)
- Secondary Outcome Measures
Name Time Method Bone density(total hip, femoral neck),Bone metabolic marker
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms differentiate denosumab (RANKL inhibitor) and romosozumab (sclerostin antibody) in postmenopausal osteoporosis treatment?
How does the efficacy of denosumab versus romosozumab compare to bisphosphonates in postmenopausal osteoporosis patients?
Which biomarkers correlate with improved bone mineral density outcomes in JPRN-jRCT1041200090 denosumab/romosozumab study?
What adverse events are observed in JPRN-jRCT1041200090 comparing denosumab and romosozumab for postmenopausal osteoporosis?
How do denosumab and romosozumab compare to emerging RANKL pathway modulators in postmenopausal osteoporosis management?